nach oben

Erschienen in:

01.01.2009 | Original Research Article

Drug-Induced Liver Injury Network (DILIN) Prospective Study

Rationale,Design and Conduct

verfasst von: Dr Robert J. Fontana, Paul B. Watkins, Herbert L. Bonkovsky, Naga Chalasani, Timothy Davern, Jose Serrano, James Rochon, the DILIN Study Group

Erschienen in: Drug Safety | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Background: Drug-induced liver injury (DILI) is an uncommon adverse drug reaction of increasing importance to the medical community, pharmaceutical industry, regulatory agencies and the general public.

Objectives: The Drug-Induced Liver Injury Network (DILIN) was established to advance understanding and research into DILI by initiating a prospective registry of patients with bona fide DILI for future studies of host clinical, genetic, environmental and immunological risk factors. The DILIN was also charged with developing standardized nomenclature, terminology and causality assessment instruments.

Methods: Five clinical sites, a data coordinating centre and senior scientists from the National Institute of Diabetes and Digestive and Kidney Diseases initiated the DILIN prospective study in September 2004. Eligible patients are required to meet minimal laboratory or histological criteria within 6 months of DILI onset and have other competing causes of liver injury excluded. Patients in the general community setting with pre-existing HIV, hepatitis B virus or hepatitis C virus infections and/or abnormal baseline liver biochemistries are eligible for enrolment. In addition, subjects with liver injury due to herbal products are eligible to participate. Control patients without DILI are also to be recruited in the future.

Results: All referred subjects undergo an extensive review of available laboratory, pathology and imaging studies. Subjects who meet pre-defined eligibility criteria at the 6-month study visit are followed for 2 years to better define the natural history of chronic DILI. Causality assessment is determined by a panel of three hepatologists who independently assign a causality score ranging from 1 (definite) to 5 (unlikely) as well as a severity score ranging from 1 (mild) to 5 (fatal). During the first 3 years, 367 subjects were enrolled into the DILIN prospective study. Conclusion: DILIN is a multicentre research network charged with improving our understanding of the aetiologies, risk factors and outcomes of DILI in the US. The network is meeting the targeted enrolment of ten patients per month and is developing a repository of clinical data and biological samples for future studies of DILI pathogenesis and outcome.

Ostapowicz G, Fontana RJ, Schiodt RV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947–54PubMed

Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxciol Pathol 2005; 33: 155–64CrossRef

Favreau JT, Ryu ML, Braunstein G, et al. Severe hepatoxicity associated with the dietary supplement Lipokinetix. Ann Intern Med 2002; 136: 590–5PubMed

Stickel F, Baumuller HM, Seitz K, et al. Hepatitis induced by Kava (Piper methysticum rhizome). J Hepatol 2003; 39: 62–7PubMedCrossRef

Bjornson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42: 481–9CrossRef

Watkins PB, Seeff LB. Drug induced liver injury: summary of a single topic clinical research conference. Hepatology 2006; 43: 618–31PubMedCrossRef

Walgren JL, Mitchell MD, Thompson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 2005; 35: 325–61PubMedCrossRef

Navarro VJ, Senior JR. Drug related hepatotoxicity. N Engl J Med 2006; 354: 731–9PubMedCrossRef

Andrade RJ, Lucena I, Alonso A, et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 2004; 39: 1603–12PubMedCrossRef

10.

Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001; 33: 308–10PubMedCrossRef

11.

Verma A, Lilienfeld DE. The need for a population-based surveillance system for liver disease in the United States. Pharmacoepidemiol Drug Saf 2004; 13: 821–4PubMedCrossRef

12.

Hoofnagle JH. Drug induced liver injury network (DILIN). Hepatology 2004; 40: 773PubMed

13.

Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473–83PubMedCrossRef

14.

Varni JW, Burwinkle TM, Seid M, et al. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr 2003; 3: 329–41PubMedCrossRef

15.

Nunez M, Soriano V. Hepatotoxicity of antiretrovirals: incidence, mechanisms, and management. Drug Saf 2005; 38: 53–66

16.

Ogedegbe AO, Sulkowski MS. Antiretroviral-associated liver injury. Clin Liver Dis 2003; 7: 475–99PubMedCrossRef

17.

Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999–2002. Am J Gastroenterol 2006; 101: 76–82PubMedCrossRef

18.

Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut 1999; 44: 731–5PubMedCrossRef

19.

Kleiner DA, Chalasani NP, Conjeevaram HS, et al. Relationship of biochemical to histologic findings and the pathological pattern of injury among cases identified in the NIH drug induced liver injury network (DILIN) study [abstract]. Gastroenterology 2007; 132: M1775

20.

Andrade RJ, Lucerna MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512–21PubMed

21.

Shapiro MZ, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 2007; 11: 477–505PubMedCrossRef

22.

Danan G, Benichou C. Causality assessment of adverse reactions to drugs: a novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323–30PubMedCrossRef

23.

Chalasani N, Fontana RJ, Bonkovsky HL, for the Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug induced liver injury in the United States. Gastroenterology. Epub 2008 Sep 17

24.

Hunter DJ, Kraft P. Drinking from the fire hose: statistical issues in genome-wide association studies. N Engl J Med 2007; 357: 436–9PubMedCrossRef

25.

Ballet F. Hepatotoxicity in drug development: detection, significance and solutions. J Hepatol 1997; 26 Suppl. 2: 26–36CrossRef

26.

Fontana RJ, McCashland TM, Benner KG, et al. Acute liver failure associated with prolonged use of bromfenac 68 leading to liver transplantation. Liver Transpl Surg 1999; 5: 480–4PubMedCrossRef

27.

Graham DJ, Green L, Senior JR, et al. Troglitazone-induced liver failure: a case study. Am J Med 2003; 114: 299–306PubMedCrossRef

28.

Lee WM, Larrey D, Olsson R, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 2005; 28: 351–70PubMedCrossRef

29.

Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002. Arch Intern Med 2005; 165: 1363–9PubMedCrossRef

30.

Devalle MB, Klinteberg AV, Alem N, et al. Drug induced liver injury in a Swedish University hospital outpatient hepatology clinic. Aliment Pharmacol Ther 2006; 24: 1187–95CrossRef

31.

Galan M, Potts J, Silverman AL, et al. The burden of acute non-fulminant drug-induced hepatitis in a United States Tertiary care center. J Clin Gastroenterol 2005; 39: 64–7PubMed

32.

Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451–5PubMedCrossRef

33.

Whitehead MW, Hainsworth I, Kingham JGC. The cause of obvious jaundice in South West Wales: perceptions versus reality. Gut 2001; 48: 409–13PubMedCrossRef

34.

Ibanez L, Perez E, Vidal X, et al. Prospective surveillance of acute serious liver disease unrelated to infectious obstructive or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatology 2002; 37: 592–600CrossRef

35.

Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol 2002; 40: 3–20PubMedCrossRef

36.

LaRusso NF, Schneider BL, Black D, et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology 2006; 44: 746–64PubMedCrossRef

37.

Patel PA, Voigt MD. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol 2002; 97: 1198–203PubMedCrossRef

38.

Mok MY, Ng WL, Yuen MF, et al. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 2000; 18: 363–8PubMedCrossRef

39.

Benichou C. Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol 1990; 11: 272–6PubMedCrossRef

40.

Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 2006; 44: 1581–8PubMedCrossRef

41.

Lok ASF, McMahon B. AASLD practice guideline: chronic hepatitis B. Hepatology 2007; 45: 507–39PubMedCrossRef

42.

Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130: 231–64PubMedCrossRef

43.

Sharp JR, Ishak KG, Zimmerman HJ. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 1980; 92: 14–9PubMed

44.

Shergy WJ, Polisson RP, Caldwell DS, et al. Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. Am J Med 1988; 85: 771–4PubMedCrossRef

45.

Rockey DC, Seeff LB, Freston JW, et al. Comparison between expert opinion and RUCAM for assignment of causality in drug induced liver injury [abstract]. Gastroenterology 2007; 132: M1777

46.

Rochon J, Protiva B, Seeff LB, the Drug Induced Liver Injury Network. The reliability of the RUCAM for assessing causality in drug-induced liver injury. Hepatology 2008; 48: 1175–83PubMedCrossRef

47.

Krivoy N, Taeri M, Neuman MG. Antiepileptic drug-induced hypersensitivity syndrome reactions. CNS Drugs 2004; 18: 5–25CrossRef

Titel: Drug-Induced Liver Injury Network (DILIN) Prospective Study
Rationale,Design and Conduct
verfasst von: Dr Robert J. Fontana
Paul B. Watkins
Herbert L. Bonkovsky
Naga Chalasani
Timothy Davern
Jose Serrano
James Rochon
the DILIN Study Group
Publikationsdatum: 01.01.2009
Verlag: Springer International Publishing
Erschienen in: Drug Safety / Ausgabe 1/2009
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI: https://doi.org/10.2165/00002018-200932010-00005

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2009

Determinants of Under-Reporting of Adverse Drug Reactions

Use and Risk Management of Carvedilol for the Treatment of Heart Failure in the Community in England

Platelet Measurements versus Discharge Diagnoses for Identification of Patients with Potential Drug-Induced Thrombocytopenia

An Intervention to Improve Spontaneous Adverse Drug Reaction Reporting by Hospital Physicians

Vision Disorders and Phosphodiesterase Type 5 Inhibitors

Drug-Induced Thrombocytopenia